| Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. NC Munshi, H Avet-Loiseau, AC Rawstron, RG Owen, JA Child, ... JAMA oncology 3 (1), 28-35, 2017 | 550 | 2017 |
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170, 2019 | 470 | 2019 |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ... Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018 | 460 | 2018 |
| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 354 | 2022 |
| A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma NC Munshi, H Avet-Loiseau, KC Anderson, P Neri, B Paiva, M Samur, ... Blood Advances 4 (23), 5988-5999, 2020 | 342 | 2020 |
| Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma G Görgün, MK Samur, KB Cowens, S Paula, G Bianchi, JE Anderson, ... Clinical cancer research 21 (20), 4607-4618, 2015 | 334 | 2015 |
| Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma MK Samur, M Fulciniti, A Aktas Samur, AH Bazarbachi, YT Tai, ... Nature communications 12 (1), 868, 2021 | 309 | 2021 |
| Genomic landscape and chronological reconstruction of driver events in multiple myeloma F Maura, N Bolli, N Angelopoulos, KJ Dawson, D Leongamornlert, ... Nature communications 10 (1), 3835, 2019 | 283 | 2019 |
| Genomic patterns of progression in smoldering multiple myeloma N Bolli, F Maura, S Minvielle, D Gloznik, R Szalat, A Fullam, ... Nature communications 9 (1), 3363, 2018 | 208 | 2018 |
| Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set A Chari, MK Samur, J Martinez-Lopez, G Cook, N Biran, K Yong, ... Blood, The Journal of the American Society of Hematology 136 (26), 3033-3040, 2020 | 207 | 2020 |
| RTCGAToolbox: a new tool for exporting TCGA Firehose data MK Samur PloS one 9 (9), e106397, 2014 | 178 | 2014 |
| Widespread intronic polyadenylation diversifies immune cell transcriptomes I Singh, SH Lee, AS Sperling, MK Samur, YT Tai, M Fulciniti, NC Munshi, ... Nature communications 9 (1), 1716, 2018 | 165 | 2018 |
| ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-Amplified multiple myeloma M Marchesini, Y Ogoti, E Fiorini, AA Samur, L Nezi, M D'Anca, P Storti, ... Cancer Cell 32 (1), 88-100. e6, 2017 | 152 | 2017 |
| MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer Y Yasumizu, H Rajabi, C Jin, T Hata, S Pitroda, MD Long, M Hagiwara, ... Nature communications 11 (1), 338, 2020 | 135 | 2020 |
| MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer A Bouillez, H Rajabi, C Jin, M Samur, A Tagde, M Alam, M Hiraki, ... Oncogene 36 (28), 4037-4046, 2017 | 125 | 2017 |
| The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival H Ohguchi, T Hideshima, MK Bhasin, GT Gorgun, L Santo, M Cea, ... Nature communications 7 (1), 10258, 2016 | 111 | 2016 |
| Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines F Maura, M Petljak, M Lionetti, I Cifola, W Liang, E Pinatel, LB Alexandrov, ... Leukemia 32 (4), 1043-1047, 2018 | 110 | 2018 |
| Bortezomib induces anti–multiple myeloma immune response mediated by cGAS/STING pathway activation A Gulla, E Morelli, MK Samur, C Botta, T Hideshima, G Bianchi, M Fulciniti, ... Blood cancer discovery 2 (5), 468-483, 2021 | 108 | 2021 |
| Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma A Gullà, T Hideshima, G Bianchi, M Fulciniti, M Kemal Samur, J Qi, YT Tai, ... Leukemia 32 (4), 996-1002, 2018 | 101 | 2018 |
| Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance Y Song, S Li, A Ray, DS Das, J Qi, MK Samur, YT Tai, N Munshi, ... Oncogene 36 (40), 5631-5638, 2017 | 96 | 2017 |
